RedHill Biopharma announced the issue of a new Chinese patent Notice of Allowance covering opaganib as a therapyg for inhibition of single-stranded RNA virus replication (notably Ebola Disease Virus) from the Chinese National Intellectual Property Administration, valid through 2035.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on RDHL:
- RedHill Biopharma Advances COVID-19 Antiviral Study
- RedHill Biopharma: First patient enrolled in government-supported COVID-19 study
- RedHill Biopharma’s Strategic Pivot and Financial Turnaround
- RedHill Biopharma Announces Full-Year 2023 Results and Operational Highlights
- RedHill Biopharma Secures $1.25M in Direct Offering